Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code AGR

16. Specific lobbying issues

Climate Change
---S. 1251/H.R. 2820: The Growing Climate Solutions Act of 2020
---FY 2022 Appropriations
---Climate Risk Disclosures
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech

Funding for the USDA
---FY 2022 Budget Resolution
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Genetically Engineered (GE) Animals
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 273: Prevention of Escapement of Genetically Altered Salmon in the United States Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

Genetically Engineered (GE) Plants
---Climate Issues & impact on the agriculture, food, and forestry sectors

USDA/APHIS Agricultural Biotechnology Regulations
---The Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) Rule under the Plant Protection Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), White House Office, Environmental Protection Agency (EPA), Natl Economic Council (NEC), Food & Drug Administration (FDA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ANI

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 273: Prevention of Escapement of Genetically Altered Salmon in the United States Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Environmental Protection Agency (EPA), Natl Economic Council (NEC), U.S. Trade Representative (USTR), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 5376: Build Back Better Act
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
--- Implementation of the Families First Coronavirus Response Act of 2020

Funding for Antimicrobial Resistance (AMR) Programs
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 5376: Build Back Better Act
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
--- Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Budget Resolution
--- H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
--- USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Funding for FDA
---FY 2022 Budget Resolution
--- H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities

Funding for Health Resources and Services Administration (HRSA)

Funding for National Institutes of Health
---H.R.133: Consolidated Appropriations Act for FY 2021
---Advanced Research Projects Agency for Health (ARPA-H)


Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.R.1319: American Rescue Plan Act of 2021
--- Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic

Funding for the USDA
--- H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---Biotechnology and Agriculture Trade Program
---FY 2022 Budget Resolution
--- USDA Climate-Smart Agriculture and Forestry Partnership Initiative

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Agriculture - Dept of (USDA), White House Office, Natl Institutes of Health (NIH), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CHM

16. Specific lobbying issues

Funding for Renewable Chemicals/Bio-based Products
---FY 2022 Budget Resolution
--- H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
--- H.R. 5376: Build Back Better Act
--- USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
--- H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act;
---H.R.2532: Renewable Chemicals Act of 2021
---FY 2022 Budget Resolution
--- Investment Tax Credit
--- Production Tax Credit
---Climate Issues & impact on the agriculture, food, and forestry sectors
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021
--- H.R. 2891 Preserve Access to Affordable Generics and Biosimilars
---General

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act
---March-In Rights
---NIST Proposed Rulemaking on Bayh-Dole

Compulsory Licensing
--- H.R.4811 - Medicare Negotiation and Competitive Licensing Act of 2021
--- Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
--- Prescription Drug Price Relief Act (Discussion Draft)
--- We Protect American Investment in Drugs Act (Discussion Draft)

Coronavirus (COVID-19) Pandemic
---Restrictions on Intellectual Property Rights
---TRIPS Waiver

Diversity in Patenting
---35 USC Section 101 on Patent Eligibility
---S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021

Drug Patenting
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021
---S.1435: Affordable Prescriptions for Patients Act of 2021
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
---Restrictions on Intellectual Property Rights

Intellectual Property Enforcement
---China
---TRIPS Waiver

Inter Partes Review
--- S.2891 Restoring the America Invents Act
--- S.2774 Pride in Patent Ownership Act
---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft)

Patent Reform
---S.1260: United States Innovation and Competition Act of 2021
------Ownership and Assignments of Patents
--- S.2774 Pride in Patent Ownership Act
---Patent Litigation Reforms

Patenting of Biological Inventions
---35 USC Section 101 on Patent Eligibility
---Section 101 Modernization

United States-Mexico-Canada Agreement (USMCA)
---Implementation of USMCA

US-China Trade Agreement
---IP Provisions

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENG

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.2118: Clean Energy for America Act of 2021
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 5376: Build Back Better Act
---FY 2022 Budget Resolution
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Biorefineries (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Climate Change
---FY 2022 Budget Resolution
---S. 1251/H.R. 2820: The Growing Climate Solutions Act of 2020
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act;
---H.R. 5376: Build Back Better Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Budget Resolution
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 5376: Build Back Better Act
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Renewable Fuel Standard (RFS)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 5376: Build Back Better Act
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---FY 2022 Budget Resolution
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Cellulosic Registration Applications for Corn Kernel Fiber
---Climate Issues & impact on the agriculture, food, and forestry sectors
---RFS Reform
---Small Refinery Waivers
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---RFI from House Select Committee on the Climate Crisis
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FOO

16. Specific lobbying issues

Genetically Engineered (GE) Animals
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 273: Prevention of Escapement of Genetically Altered Salmon in the United States Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Environmental Protection Agency (EPA), Natl Economic Council (NEC), White House Office, U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code FUE

16. Specific lobbying issues

Biofuels (Non-Funding)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---H.R.3249/S.1841: Financing Our Energy Future Act of 2019
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.2118: Clean Energy for America Act of 2021
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 5376: Build Back Better Act
---FY 2022 Budget Resolution
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Biorefineries (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors

Climate Change
---FY 2022 Budget Resolution
---S. 1251/H.R. 2820: The Growing Climate Solutions Act of 2020
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act;
---H.R. 5376: Build Back Better Act
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Budget Resolution
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 5376: Build Back Better Act
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

Renewable Fuel Standard (RFS)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---H.R.5305: Extending Government Funding and Delivering Emergency Assistance Act
---H.R. 5376: Build Back Better Act
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---FY 2022 Budget Resolution
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Cellulosic Registration Applications for Corn Kernel Fiber
---Climate Issues & impact on the agriculture, food, and forestry sectors
---RFS Reform
---Small Refinery Waivers
---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel
---RFI from House Select Committee on the Climate Crisis
---USDA Climate-Smart Agriculture and Forestry Partnership Initiative

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

21st Century Cures Act 2.0
---House Energy and Commerce Discussion Draft
---RFI from House Energy and Commerce Committee

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
--- Implementation of 21st Century Cures Act of 2016
--- Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
--- Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
--- Implementation of the Families First Coronavirus Response Act of 2020
---White House National Biodefense Strategy

Biosimilars
---BSUFA Negotiations
---Reimbursement
--- H.R. 2891/S.1428, the Preserve Access to Affordable Generics and Biosimilars Act;

Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.869/S.289: Research Investment to Spark the Economy (RISE) Act of 2021
---H.R.1319: American Rescue Plan Act of 2021
---COVID-19 Lessons Learned
---COVID-19 Pricing-Related Provisions
---COVID-19 Vaccine Distribution
---Defense Production Act (DPA)
---Drug Supply Chain Management
---Healthcare Disparities
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
--- Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
--- Implementation of the Families First Coronavirus Response Act of 2020,
---Medicare Reimbursement Policies
---Monoclonal Antibody Coverage and Utilization
---Patient Cost-Sharing and Smoothing
---PREP Act COVID-19 Declaration Coverage for Private Sector Procurement
---R&D Funding for Medical Countermeasures
---Senate HELP Pandemic Preparedness White Paper
---Supply Chain Issues
---TRIPS IP Waiver
---Temporarily Refundable R&D Credit
---NOL Monetization

Diagnostics and Personalized Medicine Regulation and Oversight
--- VALID Act (Discussion Draft)

Diversity & Inclusion
---Clinical Trial Diversity
---ENACT Act
---DEPICT Act
---DIVERSE Act

Drug Evaluation and Review
---COVID-19 Lessons Learned
---Compassionate Use/Expanded Access
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---Patient-Focused Drug Development
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Innovation Incentives
---Prescription Drug User Fee Act (PDUFA) VII Priorities
---Priority Review Voucher Programs
---Promising Pathway Act (Discussion Draft)
---Regulatory Reform & Modernization
---Use of Real-World Evidence
---Advisory Committee Enhancements

Drug Importation
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)

Drug Manufacturing, Quality & Distribution
---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft)
---Inspections

Drug Patenting
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021
--- H.R. 2891 Preserve Access to Affordable Generics and Biosimilars
---S.1435: Affordable Prescriptions for Patients Act of 2021
---Lower Health Care Costs for Patients Act (Discussion Draft)
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---S.1435: Affordable Prescriptions for Patients Act of 2021
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R. 2883/S.1425: the Stop Stalling Access to Affordable Medications;
---H.R. 2891/S.1428: the Preserve Access to Affordable Generics and Biosimilars Act;
---H.R. 2873: the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021;
---H.R. 2884: the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act;
---H.R. 3684 - Infrastructure Investment and Jobs Act?
---S.1435, Affordable Prescriptions for Patients Act of 2021
---S.632/H.R. 1732, IDEA Act
---HR 5125 Strengthening Innovation in Medicare/Medicaid
---EO 14036 on Competition in American Economy Under importation
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Drug Pricing Provisions
---Medicare Drug Price Negotiation Act (Discussion Draft)
---Prescription Drug Pricing Reduction Act (Discussion Draft)
---Reference Pricing in Drug Reimbursement
---Senate Finance Committee Drug Pricing Principles
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)

Funding for Antimicrobial Resistance Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 4127, the DISARM Act
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 5376: Build Back Better Act
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for FDA
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities

Funding for Health Resources and Services Administration (HRSA)
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021

Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Advanced Research Projects Agency for Health (ARPA-H)

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Medicaid
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021
---Pricing and Rebates
---Senate Finance Committee Drug Pricing Principles
---Value-Based Purchasing (VBP) Rule
---Alternative Payment Arrangements for Gene Therapies
---Drug Benefit Design

Opioid Crisis
---FDA Reforms

Orphan Drug Issues
---H.R. 5376: Build Back Better Act
---Tax Credit

Reimbursement and Coverage of Innovative Products
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---Administrative Rebate Rule
---CMMI Authority
---Drug Pricing Provisions
---Medicare Part B Physician-Administered Products
---New Opportunities for Value that Extend Lives (NOVEL) Act (Discussion Draft)
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Reference Pricing in Drug Reimbursement
---Senate Finance Committee Drug Pricing Principles
---Step Therapy
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
---Value-Based Purchasing (VBP) Rule


Vaccines and Infectious Diseases
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.550: Immunization Infrastructure Modernization Act
---H.R.951: Maternal Vaccinations Act
---H.R.979: Vaccine Fairness Act
---H.R.1319: American Rescue Plan Act of 2021
---H.R.1452: A bill to direct the Secretary of Health and Human Services to publish the formula the Secretary uses to determine the allocation of COVID-19 vaccines, and for other purposes.
---H.R.1550: Promoting Resources to Expand Vaccination, Education, and New Treatments for (PREVENT) HPV Cancers Act of 2021
---H.R.1978: Protecting Seniors through Immunizations Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021
---H.R.3013: COVID Vaccine Transportation Access Act
---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021
---H.R.3742: Vaccine Information for Nursing Facility Operators (INFO) Act
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---H.R.4127: A bill to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes.
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---Adult Immunization
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Vaccine Injury Compensation Program
---Vaccine and Antimicrobial Resistance Product Development and Incentives

Vaccine Injury Compensation Program
---FY 2022 Appropriations
---H.R.3656: Vaccine Access Improvement Act of 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Natl Institutes of Health (NIH), Natl Security Council (NSC), Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), Office of Science & Technology Policy (OSTP), Small Business Administration (SBA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-Funding)
---White House National Biodefense Strategy

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Natl Security Council (NSC), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---White House National Biodefense Strategy
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---Pandemic Preparedness Planning

Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Immunization Information Systems
---R&D Funding for Medical Countermeasures
---Senate HELP Pandemic Preparedness White Paper

Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Funding for Medical Countermeasures
---Senate HELP Pandemic Preparedness White Paper
---Immunization Information Systems
---Defense Production Act
---Supply Chain

Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---Advanced Research Projects Agency for Health (ARPA-H)

Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Natl Security Council (NSC), Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee

340B Drug Discount Program
---H.R.3203: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
---Program Implementation & Oversight

Coronavirus (COVID-19) Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---Patient Cost-Sharing and Smoothing
---COVID-19 Pricing Related Provisions
---Immunization Information Systems

Drug Manufacturing, Quality & Distribution
---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft)

Drug Pricing
---FY 2022 Appropriations
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.5260: Reduced Costs and Continued Cures Act
---S.2327 - Seniors Prescription Drug Relief Act
---H.R. 5376: Build Back Better Act
---H.R.3684: Infrastructure Investment and Jobs Act
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Drug Pricing Provisions
---Prescription Drug Pricing Reduction Act (Discussion Draft)
---Reference Pricing in Drug Reimbursement
---Senate Finance Committee Drug Pricing Principles
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)

Medicaid
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021
--- Alternative payment arrangements for gene therapies
---Drug Benefit Design
---Pricing and Rebates
---Senate Finance Committee Drug Pricing Principles
---Value-Based Purchasing (VBP) Rule

Reimbursement and Coverage of Innovative Products
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---Administration Rebate Rule
---CMMI Authority
---Drug Pricing Provisions
---Medicare Part B Physician-Administered Products
---New Opportunities for Value that Extend Lives (NOVEL) Act (Discussion Draft)
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Reference Pricing in Drug Reimbursement
---Senate Finance Committee Drug Pricing Principles
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
---Step Therapy
---Value-Based Purchasing (VBP) Rule
---Value-based Contracting and Communications

Vaccines and Infectious Diseases
---H.R.1978: Protecting Seniors through Immunizations Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021
---H.R.4127: A bill to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Formation Incentives
---H.R.2140/S.961: American Innovation Act
---H.R.3448: Helping Startups Continue to Grow Act
---H.R. 5376: Build Back Better Act
---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft)
---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft)
---IGNITE American Innovation Act (Discussion Draft)
---Reform of Net Operating Loss Rules

Capital Market Enhancements
---Market Liquidity Proposals

Short Selling Transparency
---H.R. 4681-Short Sale Transparency and Fairness Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Capital Formation Incentives
---H.R.2140/S.961: American Innovation Act
---H.R.3448: Helping Startups Continue to Grow Act
---H.R. 5376: Build Back Better Act
---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft)
---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft)
---Incentives for Sustainable Aviation Fuels
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933
---IGNITE American Innovation Act (Discussion Draft)
---Reform of Net Operating Loss Rules

Research & Development Tax Credit Reforms
---H.R.2140/S.961: American Innovation Act
---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft)
---Expensing of R&D Expenditures

Vaccine Injury Compensation Program
---H.R.3656: Vaccine Access Improvement Act of 2021

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Digital Trade
---EU Digital Strategy

Drug Pricing
---Drug pricing and reimbursement policy in Taiwan
---Reference Pricing in Drug Reimbursement

Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech

Intellectual Property International Enforcement
---China
---TRIPS Waiver

The United States-Mexico-Canada Agreement (USMCA)
---Implementation of United States-Mexico-Canada Agreement (USMCA)
------Ag-Biotech Provisions
------IP Provisions
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech

US-China Trade Agreement
---Ag-Biotech Provisions
---IP Provisions

US-EU Trade Agreement
---Ag-Biotech Provisions

World Trade Organization
---TRIPS Waiver

World Health Organization (WHO)
---TRIPS Waiver

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Patent & Trademark Office (PTO), White House Office, Environmental Protection Agency (EPA), Natl Security Council (NSC), Natl Economic Council (NEC), Commerce - Dept of (DOC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes